Coluracetam is a quinoline-fused racetam developed by BrainCells Inc. for major depressive disorder. It enhances high-affinity choline uptake. Phase 2 trials were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
2-Pyrrolidinone-based racetam nootropic and high-affinity choline uptake enhancer
A synthetic racetam derivative developed at Mitsubishi Tanabe Pharma as a high-affinity choline uptake enhancer for Alzheimer’s disease, subsequently repositioned for major depressive disorder with comorbid generalized anxiety disorder, and distinguished from other racetams by a primary mechanism of action centered on choline transporter modulation rather than direct receptor agonism.
Abstract
Coluracetam (MKC-231, BCI-540) is a synthetic nootropic compound of the racetam structural class, characterized by a 2-oxopyrrolidinylacetamide pharmacophore fused to a tetrahydrofuroquinoline ring system, and distinguished from other racetam-class agents (piracetam, aniracetam, pramiracetam, oxiracetam) by a primary mechanism of action centered on the enhancement of high-affinity choline uptake (HACU), the rate-limiting step in acetylcholine biosynthesis. The compound was synthesized at the Mitsubishi Tanabe Pharma Corporation in the early 1990s as part of a medicinal chemistry program targeting cholinergic neurotransmission deficits in Alzheimer’s disease. Preclinical characterization in the ethylcholine aziridinium (AF64A) cholinotoxin rat model demonstrated that oral administration of MKC-231 at 0.3 to 10 mg/kg produced dose-dependent restoration of hippocampal high-affinity choline uptake activity, normalization of acetylcholine synthesis and release in hippocampal synaptosomes, and long-lasting cognitive improvement in Morris water maze and Y-maze paradigms that persisted beyond the elimination of the compound from plasma, suggesting a durable regulatory change in choline transporter (CHT1) expression or trafficking rather than a transient pharmacodynamic effect [1, 2, 3]. The Murai et al. (1994) study in ethylcholine aziridinium-treated mice provided the initial demonstration that MKC-231 ameliorated working memory deficits and restored hippocampal acetylcholine levels without producing the tremor, salivation, or hypothermia characteristic of direct cholinomimetic agents such as tacrine [4]. The compound advanced through Phase 2 clinical trials at Mitsubishi Tanabe for Alzheimer’s disease but failed to meet primary efficacy endpoints, and development for that indication was discontinued.
In 2006, BrainCells, Inc. in-licensed coluracetam under the designation BCI-540 and repositioned it for major depressive disorder (MDD) with comorbid generalized anxiety disorder (GAD). A Phase 2a randomized, double-blind, placebo-controlled trial in 101 evaluable patients with treatment-resistant MDD (defined as failure of an average of two prior antidepressant trials) reported no statistically significant benefit of BCI-540 at 80 mg once daily or three times daily over placebo in the overall population at six weeks on either the Hamilton Rating Scale for Depression (HAM-D) or the Hamilton Rating Scale for Anxiety (HAM-A). However, a pre-specified subgroup analysis in patients with comorbid MDD and GAD demonstrated a 12.2-point improvement on the HAM-D in the three-times-daily dosing cohort compared to 5.5 points in the placebo group (p < 0.008), and a corresponding improvement in anxiety symptoms [5]. The compound was well tolerated in this trial, with a side-effect profile similar to placebo. BrainCells, Inc. subsequently ceased active operations, and no further clinical trials have been reported.
Beyond the cholinergic mechanism, coluracetam has been characterized as a positive modulator of AMPA-type glutamate receptors (an “ampakine” property shared with aniracetam and some other racetams), though this activity is less well characterized than the HACU enhancement and the functional contribution to the in vivo pharmacology is uncertain [6]. The compound is not approved by any regulatory authority for any indication. It is supplied as a research-grade preparation by multiple chemical suppliers and is used in nootropic research contexts. Investigators should obtain analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, synthesis, and structural class of coluracetam; the HACU enhancement mechanism and supporting molecular pharmacology; the pharmacokinetic profile; the preclinical evidence base in cholinergic deficit models; the clinical evidence from the Phase 2a MDD/GAD trial; sourcing and quality verification; reconstitution and handling; stack interactions; adverse events; and a comparative assessment of five racetam and cholinergic nootropic alternatives against coluracetam on five competency standards.
Read the full monograph
The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.